JHOP Articles

Skip to main content

Case Reports, Lymphoma, CAR T-Cell Therapy, Adverse Events

Anakinra Used in a Patient with Diffuse Large B-Cell Lymphoma and Steroid-Refractory Immune Effector Cell–Associated Neurotoxicity Syndrome: Case Report

Drew A. Wells, PharmD, BCPS; Kori Holman, PharmD, BCOP; Brion Randolph, MD; Dennis Marjoncu, PharmD, BCOP

Perspective

“You Have Cancer”

Joshua N. Raub, PharmD, BCPS

FDA Updates

Orserdu FDA Approved for ER-Positive Advanced or Metastatic Breast Cancer with ESR1 Mutation

FDA Updates

Jaypirca, a New BTK Inhibitor, Received FDA Accelerated Approval for Relapsed or Refractory Mantle-Cell Lymphoma

FDA Updates

FDA Approved Lunsumio for Relapsed or Refractory Follicular Lymphoma

FDA Updates

Adstiladrin, First Adenoviral Vector–Based Gene Therapy, FDA Approved for High-Risk Non–Muscle Invasive Bladder Cancer

FDA Updates

Krazati Received Accelerated FDA Approval for NSCLC with KRAS G12C Mutation

FDA Updates

Keytruda Received FDA Approval for Adjuvant Treatment of Non–Small-Cell Lung Cancer

FDA Updates

Tukysa, in Combination with Trastuzumab, Now FDA Approved for HER2-Positive Unresectable or Metastatic Colorectal Cancer

FDA Updates

Brukinsa Now FDA Approved for Patients with CLL or SLL

Page 41 of 199
Results 401 - 410 of 1986